Emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera^®) is recommended as an option for use within NHS Wales for antiretroviral treatment experienced adults infected with human immunodeficiency virus type 1(HIV-1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera^®.